<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157577">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048281</url>
  </required_header>
  <id_info>
    <org_study_id>GIUPR0001</org_study_id>
    <secondary_id>76274</secondary_id>
    <secondary_id>CA109190</secondary_id>
    <secondary_id>SU-11022007-787</secondary_id>
    <nct_id>NCT01048281</nct_id>
  </id_info>
  <brief_title>Clinical &amp; Pathological Studies of Upper Gastrointestinal Carcinoma</brief_title>
  <official_title>Clinical &amp; Pathological Studies of Upper Gastrointestinal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Our research of the biology of upper gastrointestinal cancers involves the study of tissue
      samples and cells from biopsies of persons with gastric or esophageal cancer or blood
      samples from upper gastrointestinal cancer patients and persons at high inherited risk for
      these cancers. We hope to learn the role genes and proteins play in the development of
      gastric and esophageal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Anticipated">January 2099</completion_date>
  <primary_completion_date type="Anticipated">January 2099</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>p53 activity by routine pathologic analysis</measure>
    <time_frame>time of collection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>NER activity by routine pathologic analysis</measure>
    <time_frame>time of collection</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stomach Cancer</condition>
  <condition>Gastro-Esophageal(GE) Junction Cancer</condition>
  <condition>Gastric (Stomach) Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Gastrointestinal Stromal Tumor (GIST)</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tissue tumor biopsy</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, tumor
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with gastric or esophageal cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:1. Over 18 2. Diagnosed with gastric or esophageal cancer OR at an
        increased hereditary risk for upper GI cancer

        Exclusion Criteria:1. Under 18 2. No family or personal history of gastric or esophageal
        cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James M Ford</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meredith Mills</last_name>
    <phone>(650) 724-5223</phone>
    <email>bluett@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Mills</last_name>
      <phone>650-724-5223</phone>
      <email>bluett@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>James M Ford</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hanlee P. Ji</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vandana Bhardwaj Sharma</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 12, 2016</lastchanged_date>
  <firstreceived_date>January 11, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
